Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Cardiovascular complications account for the highest mortality in type 2 diabetic patients,
mainly due to ischeamia heart disease (IHD). Most of the attention in treating IHD in type 2
diabetes is understandably directed toward treating coronary artery conditions. However there
are other treatable culprits in these patients.
Left ventricular hypertrophy (LVH) is widespread in type 2 diabetic patients with IHD, even
in the absence of hypertension. It is a strong predictor of cardiovascular events and
all-cause mortality. In one study, the presence of LVH was a stronger predictor of mortality
than either multivessel coronary disease or impaired left ventricular function. Regression of
LVH has been associated with an improved prognosis, independent of change in blood pressure
(BP). Therefore, cardiovascular events and mortality in type 2 diabetes with IHD might will
be reduced if we can find novel therapies to regress LVH.
Pioglitazone can improve atherosclerosis. Therefore, we hypothesied that pioglitazone can
regress the left ventricular mass (LVM) in type 2 diabetes with IHD.Therefore, in this study,
we will treat patients with pioglitazone, and we will also metformin as control.